As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...

Biogen (BIIB) shares have shown some movement recently, and investors may be taking a closer look at what is driving performance. Over the past month, the stock has dipped around 3%. See our latest ...

US biotech Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3%, with GAAP diluted EPS of $3.17, ...

Biogen has emerged as a potential front-runner at the Cannes Lions International Festival of Creativity, snagging four spots on the Pharma shortlist for its work on Friedreich’s ataxia. But the ...

Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...

AMVUTTRA is an FDA-approved RNAi therapeutic for the treatment of ATTR amyloidosis, a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the nerves, heart and ...

Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a prominent contender at the Cannes Lions International Festival of Creativity ...

One of North Carolina's largest biotechnology companies is expanding its operations with a $2 billion investment. Triangle eco-devo pipeline could bring thousands of jobs $700M investment bolsters ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against ...

Biogen employees work inside a lab used to produce cell cultures in 2014 at the firm’s Research Triangle Park facilities. N&O file photo Biogen commits $2 billion to expand RTP campuses in Wake and ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.